Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 28, 2026 08:00 ET | Source: COUR Pharma

COUR Pharma Publishes Peer-Reviewed Data in Science Advances

CHICAGO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company developing ﬁrst-in-class, antigen-specific immune tolerance therapies for autoimmune diseases,...
January 28, 2026 08:00 ET | Source: BioNTech SE

BioNTech ernennt Kylie Jimenez zur neuen Personalvorständin

Mainz, Deutschland, 28. Januar 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) gab heute bekannt, dass der Aufsichtsrat Kylie Jimenez mit Wirkung zum 1. März 2026...
January 28, 2026 08:00 ET | Source: BioNTech SE

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

BioNTech appoints Kylie Jimenez as CPO, effective March 1, 2026, to drive global people strategy supporting its 2030 multi-product oncology vision.
January 27, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity

A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p < 0.001) at 48 weeks at the highest dose tested (24 mg), without...
$Refractory Follicular Lymphoma Diagnostics Market$

January 22, 2026 11:13 ET | Source: Research and Markets

Refractory Follicular Lymphoma Diagnostics Market Research 2026 - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

Dublin, Jan. 22, 2026 (GLOBE NEWSWIRE) -- The "Refractory Follicular Lymphoma Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ...
January 21, 2026 12:02 ET | Source: AB Science

AB Science obtient un brevet japonais pour l'utilisation du masitinib dans le traitement des formes progressives de la sclérose en plaques (SEP) jusqu'en 2041

COMMUNIQUÉ DE PRESSE AB SCIENCE OBTIENT UN BREVET JAPONAIS POUR L'UTILISATION DU MASITINIB DANS LE TRAITEMENT DES FORMES PROGRESSIVES DE LA SCLÉROSE EN PLAQUES (SEP) JUSQU'EN 2041 IL S'AGIT DU...
January 21, 2026 12:02 ET | Source: AB Science

AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041

PRESS RELEASE AB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL 2041 THIS IS THE FIRST COUNTRY DELIVERING THE MS PATENT ...
January 21, 2026 08:00 ET | Source: LB Pharmaceuticals Inc

LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel

NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for...
January 20, 2026 09:17 ET | Source: Spherix Global Insights

Rheumatologists Sharpen Differentiation Across the SLE Pipeline as Late-Stage Assets Crystallize into More Defined Clinical Roles, According to Spherix Global Insights

Exton, PA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Updated findings from the Q4 2025 Market Dynamix™: SLE, Pipeline Refresh reveal a maturing and increasingly stratified development landscape, as US...
January 14, 2026 03:30 ET | Source: Custom Market Insights

[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “T-Cell Engagers Market Size, Trends and Insights By Product Type (BiTEs...